[Sunitinib: 10 years after approval for the therapy of metastatic renal cell carcinoma].
Sunitinib is one of first targeted agents and tyrosine kinase inhibitors of vascular endothelial growth factor receptor (VEGFR) that approved for therapy of metastatic renal cell carcinoma. -Moreover it is among the first compounds in oncology registered after Phase 2 of clinical trials. Sunitinib was used in the United States since January 2006. For the past 10 years a wide experience of sunitinib administration has been accumulated both in practice and in clinical trials. This review summarizes the results of sunitinib studies.